Fairvalue-Calculator Fairvalue-Calculator
EN DE

Kintor Pharmaceutical Limited (KNTPF) Fair Value & Analysis

Healthcare · US · Market cap $160M

Price$0.3420
Fair Value$0.2600
Upside-24.0%
Quality95/100
Evidence: Low Range $0.1900 – $0.3200

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Kintor Pharmaceutical Limited (KNTPF) currently trades at $0.3420, while our model-based Fair Value estimate is $0.2600 — implying the stock looks roughly 24.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People's Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kina…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Kintor Pharmaceutical Limited (KNTPF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.2600 versus a price of $0.3420 — about −24% (overvalued). Model-based estimate, not financial advice.
What is the fair value of KNTPF?
Our 21-model fair value for Kintor Pharmaceutical Limited is $0.2600 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.3420.
What is the quality score of KNTPF?
Kintor Pharmaceutical Limited has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.